Corridor Pharmaceuticals is a biopharmaceutical company dedicated to developing and commercializing novel therapeutic Arginase inhibitors. Elevation of Arginase enzyme levels is associated with endothelial dysfunction, and has been shown to reduce Nitric Oxide (NO) production and increase the production of damaging reactive oxygen species (ROS).